|
Gad Berdugo MSc Eng, MBA
Managing Partner
Explorium Captial
USA
|
Mr. Berdugo is the Managing Partner of Explorium Capital LLC, a strategic and financial advisory firm
focusing on the global biotechnology sector. He currently serves as Vice Chairman of the Board of
Directors of clinical development stage precision oncology company, Diaccurate and as an Executive In
Residence for Columbia Technology Ventures. Mr. Berdugo brings over 25 years of biotech corporate &
business development, strategy, operational, financial, investment and general venture management
experience. He served as CBO at CRISPR gene editing pioneer Editas (Nasdaq EDIT); Co-founder and CEO
at personalized neoantigen cancer vaccine venture, EpiVax Oncology Inc.; CFO and EVP at Immune
Pharmaceuticals Inc. (Nasdaq IMNP); Managing Director and Head of Life Sciences at Tegris Advisors, a
strategic and financial advisory boutique; Founder and Managing Partner of the Explorium Global Life
Sciences Investment Fund; Director, Senior Equity Research Analyst and Life Sciences Sector Leader at
Lazard, Asset Management Group. Prior to that, he served as a Director of Global Business Development
within Baxter’s Biopharmaceuticals group and started his career at Abbott Labs. Mr. Berdugo received his
B.Sc. with Honors in Biotechnology from Imperial College London, his M.Sc. in Biochemical Engineering
from University College London and his M.B.A. from H.E.C. Paris. He serves on the Board of Directors of
Friends of H.E.C. Inc. and Friends of U.C.L. Inc. Mr. Berdugo is bilingual in French and English and has dual
US and French citizenships. He resides with his wife in New York City.
focusing on the global biotechnology sector. He currently serves as Vice Chairman of the Board of
Directors of clinical development stage precision oncology company, Diaccurate and as an Executive In
Residence for Columbia Technology Ventures. Mr. Berdugo brings over 25 years of biotech corporate &
business development, strategy, operational, financial, investment and general venture management
experience. He served as CBO at CRISPR gene editing pioneer Editas (Nasdaq EDIT); Co-founder and CEO
at personalized neoantigen cancer vaccine venture, EpiVax Oncology Inc.; CFO and EVP at Immune
Pharmaceuticals Inc. (Nasdaq IMNP); Managing Director and Head of Life Sciences at Tegris Advisors, a
strategic and financial advisory boutique; Founder and Managing Partner of the Explorium Global Life
Sciences Investment Fund; Director, Senior Equity Research Analyst and Life Sciences Sector Leader at
Lazard, Asset Management Group. Prior to that, he served as a Director of Global Business Development
within Baxter’s Biopharmaceuticals group and started his career at Abbott Labs. Mr. Berdugo received his
B.Sc. with Honors in Biotechnology from Imperial College London, his M.Sc. in Biochemical Engineering
from University College London and his M.B.A. from H.E.C. Paris. He serves on the Board of Directors of
Friends of H.E.C. Inc. and Friends of U.C.L. Inc. Mr. Berdugo is bilingual in French and English and has dual
US and French citizenships. He resides with his wife in New York City.